146 related articles for article (PubMed ID: 16236544)
21. Evaluation of high-throughput genotoxicity assays used in profiling the US EPA ToxCast chemicals.
Knight AW; Little S; Houck K; Dix D; Judson R; Richard A; McCarroll N; Akerman G; Yang C; Birrell L; Walmsley RM
Regul Toxicol Pharmacol; 2009 Nov; 55(2):188-99. PubMed ID: 19591892
[TBL] [Abstract][Full Text] [Related]
22. Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells.
Liu X; Zhou B; Xue L; Shih J; Tye K; Lin W; Qi C; Chu P; Un F; Wen W; Yen Y
Clin Cancer Res; 2006 Nov; 12(21):6337-44. PubMed ID: 17085643
[TBL] [Abstract][Full Text] [Related]
23. Development of a high-throughput human HepG(2) dual luciferase assay for detection of metabolically activated hepatotoxicants and genotoxicants.
Liu X; Kramer JA; Hu Y; Schmidt JM; Jiang J; Wilson AG
Int J Toxicol; 2009; 28(3):162-76. PubMed ID: 19546255
[TBL] [Abstract][Full Text] [Related]
24. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ
Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949
[TBL] [Abstract][Full Text] [Related]
25. Ribonucleotide reductase small subunit p53R2 facilitates p21 induction of G1 arrest under UV irradiation.
Xue L; Zhou B; Liu X; Heung Y; Chau J; Chu E; Li S; Jiang C; Un F; Yen Y
Cancer Res; 2007 Jan; 67(1):16-21. PubMed ID: 17210678
[TBL] [Abstract][Full Text] [Related]
26. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
[TBL] [Abstract][Full Text] [Related]
27. Improvement in radiosensitivity using small interfering RNA targeting p53R2 in esophageal squamous cell carcinoma.
Yokomakura N; Natsugoe S; Okumura H; Ikeda R; Uchikado Y; Mataki Y; Takatori H; Matsumoto M; Owaki T; Ishigami S; Aikou T
Oncol Rep; 2007 Sep; 18(3):561-7. PubMed ID: 17671702
[TBL] [Abstract][Full Text] [Related]
28. Strategy for genotoxicity testing--metabolic considerations.
Ku WW; Bigger A; Brambilla G; Glatt H; Gocke E; Guzzie PJ; Hakura A; Honma M; Martus HJ; Obach RS; Roberts S;
Mutat Res; 2007 Feb; 627(1):59-77. PubMed ID: 17141553
[TBL] [Abstract][Full Text] [Related]
29. High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the GreenScreen HC GADD45a-GFP genotoxicity assay.
Hastwell PW; Chai LL; Roberts KJ; Webster TW; Harvey JS; Rees RW; Walmsley RM
Mutat Res; 2006 Sep; 607(2):160-75. PubMed ID: 16781187
[TBL] [Abstract][Full Text] [Related]
30. Validation of a high-throughput in vitro alkaline elution/rat hepatocyte assay for DNA damage.
Gealy R; Wright-Bourque JL; Kraynak AR; McKelvey TW; Barnum JE; Storer RD
Mutat Res; 2007 Apr; 629(1):49-63. PubMed ID: 17306613
[TBL] [Abstract][Full Text] [Related]
31. Functional analysis of chemically-induced mutations at the flounder TP53 locus, the FACIM assay.
Cachot J; Couteau J; Frébourg T; Leboulenger F; Flaman JM
Mutat Res; 2004 Aug; 552(1-2):51-60. PubMed ID: 15288541
[TBL] [Abstract][Full Text] [Related]
32. Development of genotoxicity test procedures with Episkin, a reconstructed human skin model: towards new tools for in vitro risk assessment of dermally applied compounds?
Flamand N; Marrot L; Belaidi JP; Bourouf L; Dourille E; Feltes M; Meunier JR
Mutat Res; 2006 Jul; 606(1-2):39-51. PubMed ID: 16675293
[TBL] [Abstract][Full Text] [Related]
33. Further development of the beta-lactamase MutaGen assay and evaluation by comparison with Ames fluctuation tests and the umu test.
Reifferscheid G; Arndt C; Schmid C
Environ Mol Mutagen; 2005 Aug; 46(2):126-39. PubMed ID: 15880735
[TBL] [Abstract][Full Text] [Related]
34. Olaquindox-induced genotoxicity and oxidative DNA damage in human hepatoma G2 (HepG2) cells.
Zou J; Chen Q; Tang S; Jin X; Chen K; Zhang T; Xiao X
Mutat Res; 2009 May; 676(1-2):27-33. PubMed ID: 19486861
[TBL] [Abstract][Full Text] [Related]
35. Detection of potential (anti)progestagenic endocrine disruptors using a recombinant human progesterone receptor binding and transactivation assay.
Viswanath G; Halder S; Divya G; Majumder CB; Roy P
Mol Cell Endocrinol; 2008 Nov; 295(1-2):1-9. PubMed ID: 18801410
[TBL] [Abstract][Full Text] [Related]
36. Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma.
Okumura H; Natsugoe S; Yokomakura N; Kita Y; Matsumoto M; Uchikado Y; Setoyama T; Owaki T; Ishigami S; Aikou T
Clin Cancer Res; 2006 Jun; 12(12):3740-5. PubMed ID: 16778101
[TBL] [Abstract][Full Text] [Related]
37. A cell-based assay system for high-throughput screening of anti-wrinkle agents in human dermal fibroblast transfectant cells.
Huh S; Lee J; Jung E; Ham Y; Kim SS; Hyun CG; Kim YS; Park D
Biotechnol Appl Biochem; 2007 May; 47(Pt 1):27-31. PubMed ID: 17090229
[TBL] [Abstract][Full Text] [Related]
38. Comparative investigations of genotoxic activity of five nitriles in the comet assay and the Ames test.
Wu JC; Hseu YC; Chen CH; Wang SH; Chen SC
J Hazard Mater; 2009 Sep; 169(1-3):492-7. PubMed ID: 19414215
[TBL] [Abstract][Full Text] [Related]
39. In vivo Comet assay on isolated kidney cells to distinguish genotoxic carcinogens from epigenetic carcinogens or cytotoxic compounds.
Nesslany F; Zennouche N; Simar-Meintières S; Talahari I; Nkili-Mboui EN; Marzin D
Mutat Res; 2007 Jun; 630(1-2):28-41. PubMed ID: 17507283
[TBL] [Abstract][Full Text] [Related]
40. An assessment of the utility of the yeast GreenScreen assay in pharmaceutical screening.
Van Gompel J; Woestenborghs F; Beerens D; Mackie C; Cahill PA; Knight AW; Billinton N; Tweats DJ; Walmsley RM
Mutagenesis; 2005 Nov; 20(6):449-54. PubMed ID: 16291732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
